CAR-T cell therapy

CAR-T cell therapy in China

China’s NMPA has approved 9 CAR-T products, including the world’s first approved CAR-T for a solid tumour: satri-cel, targeting CLDN18.2 in advanced gastric/GEJ cancer. Potentially shorter waits and transparent cost estimates can help you plan; the hospital confirms suitability and timing. ^{[1] [6]}

Free medical-records review

Who may be considered?

Typically, adults with relapsed or refractory disease after prior lines of therapy. Each product has its own approved indication, age limits and testing requirements; these examples are not interchangeable treatment recommendations.

Large B-cell lymphoma (LBCL)

Axicabtagene ciloleucel / Yikaida; relmacabtagene autoleucel / Relma-cel; inaticabtagene autoleucel

Other products may be considered according to their approved labels. ^[3]

Eligibility is decided by the hospital’s hematology/oncology team.

Follicular lymphoma (FL) & mantle cell lymphoma (MCL)

Relmacabtagene autoleucel / Relma-cel

^[4]

Eligibility is decided by the hospital’s hematology/oncology team.

B-cell acute lymphoblastic leukaemia (B-ALL)

Inaticabtagene autoleucel / CNCT19

^[2]

Eligibility is decided by the hospital’s hematology/oncology team.

Multiple myeloma

Equecabtagene autoleucel / Fucaso; zevorcabtagene autoleucel; ciltacabtagene autoleucel / Carvykti

Eligibility is decided by the hospital’s hematology/oncology team.

Advanced gastric/GEJ adenocarcinoma

Satricabtagene autoleucel / satri-cel · CLDN18.2

For CLDN18.2-positive, HER2-negative disease after failure of at least two prior lines of therapy. ^[1]

Eligibility is decided by the hospital’s hematology/oncology team.

A written estimate before you decide

Drug list price · per infusion

Roughly ¥1.0–1.3 million (about US$140,000–180,000). This is a planning range, not a price for every product; exchange rates and product prices vary.

Additional hospital costs

An estimated ¥100,000–300,000 for apheresis, bridging treatment, inpatient stay and complication management. Complex care can cost more.

Estimates only. Request an itemised hospital quote in writing. Medical costs are paid directly to the hospital.

Our coordination fee is separate: the full-journey tier starts at US$1,900; complex cases are US$3,500. Confirm the scope and any additional charges in writing.

View coordination fees →

Plan for time in China

Typically 6–10 weeks in China, with changes possible after assessment or during treatment. The remote review takes place before travel.

Check visa requirements with the Chinese embassy. Arrange translation of records into Chinese, and plan for a family caregiver to accompany you. The hospital decides whether bridging treatment is needed and when you can travel home.

Remote medical-records review
Arrival and hospital evaluation
Apheresis: collection of your T cells
Manufacturing: about 2–4 weeks
Preparation and CAR-T infusion
About 4 weeks of monitoring, staying near the hospital

Hospitals we can help you access

We are independent and have no partnership with these hospitals. Product availability changes; the hospital confirms eligibility and availability.

Indications to enquire about; listing a disease does not confirm that a particular product is available at that hospital.